Thermo Fisher Showcases Its Next-Gen Biopharma Services & Innovations At CPHI Milan 2024

Thermo Fisher Scientific, a global leader in science, will present its latest innovations at CPHI Milan 2024, taking place from October 8-10 in Milan, Italy. At booth #7B18, company leaders will highlight how Thermo Fisher supports biotech and pharmaceutical companies across various drug development stages. The company is launching Accelerator™ Drug Development, a comprehensive CDMO and CRO service, offering customisable solutions for small molecules, biologics, and cell & gene therapies from pre-clinical stages to commercialisation.

Michael Shafer, Executive Vice President and President of biopharma services, Thermo Fisher Scientific, said “Thermo Fisher is transforming drug development and manufacturing processes to support customers as they move critical programs forward to tackle global health challenges with speed, quality and efficiency,” he also stated, “We connect the steps between discovery and delivery – from early testing and analytical support to clinical research design to trial conduct, clinical supply chain management, manufacturing and commercial scale-up – and we strive to ensure a seamless transition, mitigate risks and accelerate innovation at every stage.”

Thermo Fisher has expanded its facilities in Cincinnati, Ohio, and Bend, Oregon, to support drug development further, enhancing pre-clinical oral drug development capabilities. The company has also bolstered its global clinical trial network, adding a new ultra-cold GMP facility in Bleiswijk, Netherlands, improved label printing and packaging solutions in Basel, Switzerland, and expanded logistics operations in Buenos Aires, Argentina. Plus, an innovation lab in Center Valley, Pennsylvania, focuses on addressing clinical trial challenges through forward-thinking solutions.

Thermo Fisher is also advancing patient-centric drug delivery methods by collaborating with the Stevanato Group to streamline production of the Vertiva® on-body delivery system. In Monza, Italy, the company has introduced next-gen technologies like augmented and virtual reality at its new Training Center and Aseptic Academy to enhance sterile manufacturing.

In addition, Thermo Fisher’s PPD™ clinical research business is expanding its global laboratory services with a new bioanalytical lab in Gothenburg, Sweden, to accelerate health innovation. The company is also partnering with DHL Express to make clinical research more sustainable, using GoGreen Plus services and investing in sustainable aviation fuel to cut emissions from air transportation by up to 80%.

Thermo Fisher’s experts will participate in several sessions at CPHI Milan on October 8th and 9th, the sessions include:

• Navigating Shifts in CDMO-Pharma Relations: Trends and Implications, Faye Boeckman, senior director, market development, pharma services, on Tuesday, Oct. 8, at 11:35-12:30 CET, Hall 5 – 5B49.

  
  

• Fireside Chat: Navigating Outsourcing Partnerships for Start-Ups, Kelly Howard, vice president, commercial operations, viral vector services global and advanced therapies, pharma services, on  Tuesday, Oct. 8, at 01:15-01:40 CET, Hall 5 – 5B49.

  
  

• Optimising ADC Processes: Advanced Strategies with High-Quality Bioreagents, Dom Price, senior manager, technical sales, production chemicals and services - EMEA, bioproduction, on Tuesday, Oct. 8, at 01:45-02:10 CET, Hall 3 – 3F97.

  
  

• Development and Validation of Automated Rapid Protocols to Ensure Mycoplasma-Free Biologics, Benjamin Ziehr, manager, cell lab, clinical research, on Tuesday, Oct at 02:45-03:10 CET, Hall 5 – 5B49.

  
  

• Maximising Outsourcing and Manufacturing Success Through Strategic CDMO and CRO Partnerships, Jennifer Cannon, president, commercial operations, pharma services, on Wednesday, Oct. 9, at 01:45-02:10 CET, Hall 5 – 5B49.

  
  

To gain further information, visit thermofisher.com